Press Releases Monopar Therapeutics Inc.

Equities

MNPR

US61023L1089

Delayed Nasdaq Other stock markets 01:47:41 2024-06-06 pm EDT			5-day change	1st Jan Change
0.9241 ^USD	+14.80%		+50.87%	+171.63%

May. 24	Monopar Therapeutics Names Karthik Radhakrishnan as CFO	MT
May. 24	Monopar Therapeutics Inc. Announces CFO Changes	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Monopar Announces CFO Succession	May. 24	GL
Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline	May. 09	GL
Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting	Apr. 18	GL
Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting	Apr. 18	AQ
Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings	Apr. 16	GL
Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients	Apr. 10	GL
Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments	Mar. 28	GL
Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments	Mar. 28	AQ
Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program	Mar. 05	GL
Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial	Feb. 27	GL
Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers	Feb. 22	GL
Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers	Feb. 22	AQ
Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers	Feb. 20	GL
Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments	Nov. 09	GL
"Unleashing a Medical Revolution: Transformative Breakthroughs in Diagnosis and Treatment" VTAK, ALDX, MNPR, INBS, SIEN	Nov. 08	AQ
Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting	Nov. 01	GL
Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting	Nov. 01	AQ
Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference	23-10-10	GL
Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference	23-10-10	AQ
Monopar to Participate in the H.C. Wainwright 25th Annual Global Investment Conference	23-09-05	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Monopar Therapeutics Inc.

Equities

MNPR

US61023L1089

Press Releases

Filters